Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2025-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
董事会审计委员会对2024年度会计师事务所履职情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance and supervision of the accounting firm for the fiscal year 2024. It includes extensive information about the audit firm, their qualifications, audit fees, independence, and the audit committee's oversight activities throughout the year. The document references the audit of the 2024 financial statements and internal controls, and the issuance of an unqualified audit opinion. It is not the audit report itself but a supervisory report on the audit firm's performance and the audit committee's activities. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding full annual reports. The document length and content confirm it is not a brief announcement or a certification letter, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-23 Chinese
2024 年度营业收入扣除事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查意见" (Special Audit Opinion) regarding the 2024 fiscal year revenue deduction items of 瑞康医药集团股份有限公司. It references an audit report number and states that the auditors have conducted a special verification on the revenue deduction schedule prepared by the company. The document includes detailed tables of revenue deductions and explanations, and the auditors provide an opinion on the compliance of the revenue deduction schedule with Shenzhen Stock Exchange listing rules and self-regulatory guidelines. The document is not a full annual report or interim report but a standalone audit-related opinion focusing on a specific aspect of the financials (revenue deductions). It is not a mere announcement or certification but contains substantive audit opinion content. Therefore, it fits the category of Audit Report / Information (AR). The document length is 2234 characters, which is short but contains detailed audit opinion and data, not just an announcement of a report. Hence, it is not RPA or RNS. Confidence is high due to clear audit opinion and detailed financial data on revenue deductions. FY 2024
2025-04-23 Chinese
内部控制审计报告
Regulatory Filings
2025-04-23 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2025-04-23 Chinese
关于举办2024年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 about holding a 2024 annual performance explanation meeting (业绩说明会). It references that the 2024 annual report has already been disclosed on April 23, 2025, and the meeting is scheduled for May 14, 2025. The document invites investors to participate and submit questions. The content is an announcement about an upcoming investor presentation event rather than the presentation or report itself. The document length is short (1057 characters), and it does not contain financial data or detailed presentation content. Therefore, it fits best as an Investor Presentation announcement (IP) or possibly a Report Publication Announcement (RPA). However, since it is specifically about the scheduling and details of an investor meeting focused on discussing financial results and strategy, the most appropriate classification is Investor Presentation (IP).
2025-04-23 Chinese
关于2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 annual profit distribution plan of RuiKang Pharmaceutical Group Co., Ltd. It includes details about the profit distribution proposal, cash dividend plans, board and supervisory committee approvals, and risk disclosures. The document is relatively short (2895 characters) and primarily serves to inform shareholders about the proposed dividend distribution and related approvals. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on dividend amounts, approval processes, and related disclosures. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2025-04-23 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.